Simris Alg

The proposal to change the name to Simris Group AB is in line with the long-term strategy to build an international business operating across multiple industry sectors.

"As already demonstrated through our acquisition of Cyano Biotech GmbH last year, it is our goal to build Simris into a global player in the microalgae space. As we develop or acquire new competencies, we accelerate entry opportunities into new markets and gain greater access to new geographies. Our attraction to protected technology platforms, and expanded production capability, underpin our focus on opportunities that represent accretive value for shareholders." said Julian Read, CEO Simris Alg AB.

Steven Schapera, Chairman, Simris Alg AB added: "Thinking longer term, Simris Group AB will be the umbrella under which each of our future businesses sit. Our acquisition of Cyano Biotech took Simris beyond Food Supplements and B2B Biomass into the high margin biopharmaceutical space. Our intention is to build on these existing verticals, whilst retaining an interest in other complimentary fields that bring strong synergies."  

For more information contact:
Julian Read
CEO Simris Alg AB
Email: julian@simris.com
Phone: +46767888212

www.simrisalg.se

ABOUT SIMRIS ALG AB (PUBL):
Simris Alg is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds.

Simris Alg's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudoa.se.